CASP1 and Cognitive impairment: Therefore, our findings suggest that the NLRP3 inflammasome may be a new therapeutic target for cognitive impairment, and that targeting the NLRP3/Caspase-1/IL-1β signaling axis is a promising approach for the treatment of postoperative inflammation.